Stay updated on TQ05105 Tablets in Refractory aGVHD Clinical Trial
Sign up to get notified when there's something new on the TQ05105 Tablets in Refractory aGVHD Clinical Trial page.

Latest updates to the TQ05105 Tablets in Refractory aGVHD Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedFooter updates include removal of the HHS Vulnerability Disclosure link and a new Revision: v3.3.3 entry. A Revision: v3.3.2 entry was removed.SummaryDifference0.2%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedStudy status and recruitment status were updated on 2025-12-04, and the trial was marked as completed on 2025-12-08. The earlier 'Active, not recruiting' status appears to have been removed on 2024-08-06.SummaryDifference0.7%

- Check45 days agoChange DetectedNo significant changes detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedRemoved the government funding notice that warned about possible delays and directed users to cc.nih.gov and opm.gov. The banner was a non-core site-wide alert rather than part of the trial data or study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check67 days agoChange DetectedRecord History shows updates to Study Status and Recruitment Status across versions. These updates reflect changes in the trial's current state and enrollment status.SummaryDifference0.1%

- Check95 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference13%

Stay in the know with updates to TQ05105 Tablets in Refractory aGVHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TQ05105 Tablets in Refractory aGVHD Clinical Trial page.